CD19 and precursor B-cell acute lymphoblastic leukemia: Anti-CD10 and anti-CD19 antibodies have already been used to deplete B-ALL lymphoblasts in vivo [28, 29], and ADCP might contribute to this antibody’s mechanism of action.